212 related articles for article (PubMed ID: 22901350)
1. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Goodwin GM; Emsley R; Rembry S; Rouillon F;
J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Stein DJ; Ahokas AA; de Bodinat C
J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
Stein DJ; Ahokas A; Jarema M; Avedisova AS; Vavrusova L; Chaban O; Gruget C; Olivier V; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2017 May; 27(5):526-537. PubMed ID: 28298261
[TBL] [Abstract][Full Text] [Related]
6. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine.
Goodwin GM; Boyer P; Emsley R; Rouillon F; de Bodinat C
Int Clin Psychopharmacol; 2013 Jan; 28(1):20-8. PubMed ID: 23151774
[TBL] [Abstract][Full Text] [Related]
7. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
10. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
[TBL] [Abstract][Full Text] [Related]
11. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.
Heun R; Ahokas A; Boyer P; Giménez-Montesinos N; Pontes-Soares F; Olivier V;
J Clin Psychiatry; 2013 Jun; 74(6):587-94. PubMed ID: 23842010
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Kennedy SH; Emsley R
Eur Neuropsychopharmacol; 2006 Feb; 16(2):93-100. PubMed ID: 16249073
[TBL] [Abstract][Full Text] [Related]
14. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
Stein DJ; Khoo JP; Picarel-Blanchot F; Olivier V; Van Ameringen M
Adv Ther; 2021 Mar; 38(3):1567-1583. PubMed ID: 33537871
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
Corruble E; de Bodinat C; Belaïdi C; Goodwin GM;
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2219-34. PubMed ID: 23823799
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
Stocchi F; Nordera G; Jokinen RH; Lepola UM; Hewett K; Bryson H; Iyengar MK;
J Clin Psychiatry; 2003 Mar; 64(3):250-8. PubMed ID: 12716265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
